Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
Viruses · 2025
DOI: 10.3390/v17070931 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Viruses, 2025. Verfasst von Umut Devrim Binay und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, Türkiye. Hauptthemen laut MEDLINE: Antiviral Agents, Carbamates, Hepatitis C, Chronic, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data from Türkiye on CHC patients treated with SOF/VEL/VOX. The present study was conducted by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK). It was a multicenter, retrospective, observational study. The data were collected from patients receiving SOF/VEL/VOX therapy at 12 medical centers in Türkiye between 1 June 2022 and 31 December 2024. The patients had received the treatment for 8 to 12 weeks. Of the 139 patients enrolled, 63.3% (n = 88) were male, with a mean age of 54.4 years. Most patients were non-cirrhotic (94.2%, n = 131) and treatment-naïve (92%, n = 128); 49.6% (n = 69) were infected with genotype 1b. Early virologic response (EVR) could be assessed in 126 patients, with an EVR rate of 82.5% (n = 104). End-of-treatment data were available for 113 patients, all achieving an end-of-treatment response. Among the 80 patients for whom week-12 post-treatment data were available, 97.5% sustained virologic response at week 12 (SVR12). Significant improvements were observed in AST, ALT, and platelet levels, along with reductions in APRI and FIB-4 scores (p = 0.001).” No serious adverse events leading to treatment discontinuation were reported. Mild adverse events included pruritus (2.1%, n = 3), fatigue (2.1%, n = 3), and nausea (1.4%, n = 2). The SOF/VEL/VOX combination is a highly effective and well-tolerated treatment option in treatment-naïve CHC patients, achieving an SVR12 rate of 97.5%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03030 Afyonkarahisar, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Mersin University, 33343 Mersin, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, 72070 Batman, Türkiye.
ORCID-Profile: Umut Devrim Binay, Faruk Karakeçili, İlhami Çelik, Leyla Dursun, Güle Çınar, Özgür Günal, Ali Asan, Eyüp Arslan, Fatma Yılmaz Karadağ, Orçun Barkay, İrem Akdemir, Zeynep Ravza Eğilmez
Zitieren
APA
Binay, U. D., Karakeçili, F., Aygen, B., Kılınç Toker, A., Çelik, İ., Demirtürk, N., Şimşek Bozok, T., Dursun, L., Akgül, F., Çınar, G., Günal, Ö., Asan, A., Arslan, E., Yılmaz Karadağ, F., Barkay, O., Akdemir, İ., Şimşek, F., Türkoğlu Yılmaz, E., Eğilmez, Z. R., …, & The Viral Hepatitis Study Group Of The Turkish Society Of Clinical Microbiology And Infectious Dise… (2025). Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye. Viruses. https://doi.org/10.3390/v17070931
Vancouver
Binay UD, Karakeçili F, Aygen B, Kılınç Toker A, Çelik İ, Demirtürk N, et al. Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye. Viruses. 2025. doi:10.3390/v17070931
BibTeX
@article{Binay2025,
author = {Binay, Umut Devrim and Karakeçili, Faruk and Aygen, Bilgehan and Kılınç Toker, Ayşin and Çelik, İlhami and Demirtürk, Neşe and Şimşek Bozok, Tuğçe and Dursun, Leyla and Akgül, Fethiye and Çınar, Güle and Günal, Özgür and Asan, Ali and Arslan, Eyüp and Yılmaz Karadağ, Fatma and Barkay, Orçun and Akdemir, İrem and Şimşek, Funda and Türkoğlu Yılmaz, Emine and Eğilmez, Zeynep Ravza and Tekin, Süda and The Viral Hepatitis Study Group Of The Turkish Society Of Clinical Microbiology And Infectious Dise…, The Viral},
title = {Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17070931}
}
EUVIMED